Lux Biosciences GmbH

Lux Biosciences is a privately held biotechnology company dedicated to the identification, optimization, development and commercialization of products for the treatment of ophthalmic diseases. The company’s business strategy is characterized by:
• A focus on compounds already marketed or with clinical proof-of-concept in non-ophthalmic indications that Lux will develop as unique, targeted therapies for corresponding ophthalmic diseases, with potentially greater efficacy and safety than existing treatments.
• A clinical and preclinical stage portfolio of projects including a next-generation calcineurin inhibitor with potential in several ophthalmic diseases and, as such, represents a pipeline of product opportunities. Lux plans to begin pivotal clinical testing for the first indication by early 2007 and – if successful – this product will reach the market in 2009.
This strategy is being implemented by an experienced, execution-oriented management team that combines a history of achievement in drug development and commercialization with deep insight and scientific expertise in the fields of immunology and ophthalmology.

Details


Adresse:
Lux Biosciences GmbH

Rubensstr. 14
60596 Frankfurt am Main
Deutschland
Arbeitsgebiet:
Forschung & Lehre
Expansion:
international
Webseite:
Gründungsjahr:
2005